Abstract
Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.
Original language | English (US) |
---|---|
Pages (from-to) | 117-123 |
Number of pages | 7 |
Journal | Neuropsychiatry |
Volume | 2 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2012 |
ASJC Scopus subject areas
- Clinical Neurology
- Psychiatry and Mental health